Related Experiment Video
Updated: Apr 30, 2026
09:08
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.2K
CD52 is a molecular target in advanced systemic mastocytosis
Gregor Hoermann1, Katharina Blatt2, Georg Greiner3
1Department of Laboratory Medicine, matthias.mayerhofer@meduniwien.ac.at.
Summary
Advanced systemic mastocytosis (SM) is a rare cancer. Researchers found CD52 is a promising target for new therapies, as the antibody alemtuzumab effectively killed cancer cells and improved survival in mice.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Advanced systemic mastocytosis (SM) is an aggressive hematopoietic neoplasm with a poor prognosis.
- Currently, no curative therapies exist for patients with advanced SM.
- Neoplastic mast cells (MCs) in advanced SM express high levels of the CD52 antigen.
Purpose of the Study:
- To identify potential therapeutic targets for advanced SM.
- To investigate the role of CD52 as a target in advanced SM.
- To evaluate the efficacy of CD52-targeting therapy in preclinical models.
Main Methods:
- Generated a human MC cell line (MCPV-1) for functional studies.
- Investigated CD52 expression mechanisms, particularly the role of activated RAS.
- Tested the anti-cancer effects of the CD52-targeting antibody alemtuzumab in vitro and in vivo.
Main Results:
- CD52 is highly expressed on neoplastic MCs in advanced SM, but not in indolent SM or normal MCs.
- Activated RAS signaling promotes CD52 surface expression.
- Alemtuzumab induced cell death in CD52-positive neoplastic MCs and MCPV-1 cells.
- Alemtuzumab treatment significantly improved survival in mice xenotransplanted with MCPV-1 cells.
Conclusions:
- CD52 is a novel molecular marker for neoplastic mast cells in advanced SM.
- CD52 represents a potential therapeutic target for advanced SM.
- Alemtuzumab demonstrates preclinical efficacy against advanced SM via CD52 targeting.
